Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 8/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268002 | 0.84 | ACE (0.56) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL215178 | 0.84 | ACE (0.56) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL29573143 | 0.84 | ACE (0.56) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL215179 | 0.84 | ACE (0.56) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL29613833 | 0.84 | ACE (0.56) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL3338649 | 0.82 | ACE (0.62) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL16658 | 0.82 | ACE (0.62) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL478774 | 0.82 | ACE (0.62) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL21879135 | 0.81 | ITGB3 (0.47) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL20502152 | 0.81 | ITGB3 (0.47) | ITGB3ITGA2BACEPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | ITGB3 2939/4885ITGA2B 2911/4885ACE 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.